PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT			
NATURE OF CONVEYANCE:			ASSIGNMENT		
CONVEYING PARTY DATA					
N			lame	Execution Date	
Eugen Uhlmann				07/11/2004	
Gerhard Breipohl				07/08/2004	
David William Will				07/19/2004	
RECEIVING PARTY DATA					
Name:	Aventis Pharma Deutschland GmbH				
Street Address:	Bruningstras	se 50			
City:	Frankfurt am	Frankfurt am Main			
State/Country:	GERMANY				
Postal Code:	D-65929				
PROPERTY NUMBERS Total: 1					
Property Type			Number		
Application Number: 12474		12474	Number 1532		
CORRESPONDENCE	DATA				
Fax Number:	(908)23	1-2626			
			hen the fax attempt is unsuccessful.		
Phone:	908-231	1-4854			
Email: linda.remer@sanofi-aventis.com					
Correspondent Name: William C. Coppola					
Address Line 1: 1041 Route 202-206 Address Line 2: Mail Code: D303-A					
Address Line 4: Bridgewater, NEW JERSEY 08807					
ATTORNEY DOCKET NUMBER:			DEAV2000/A023 US CNT 1		
NAME OF SUBMITTER:			Linda J. Remer		
Total Attachments: 3 source=DEAV2000A23 US NP1 - Assignment#page1.tif PATENT					

500968565

PATENT REEL: 023264 FRAME: 0705

PATENT REEL: 023264 FRAME: 0706

DEAV 2000/A023 US NP1

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged.

l/we

- 1) Dr. Eugen Uhlmann, Zum Talblick 31, 61479 Glashütten, Germany
- 2) Dr. Gerhard Breipohl, Richrather Straße 246, 40723 Hilden, Germany
- 3) Dr. David William Will, Kirchstrasse 21, 65830 Kriftel, Germany

The inventors are citizens of: 1); 2) Germany 3) Great Britain

hereby sell, assign, and transfer unto Aventis Pharma Deutschland GmbH , a corporation organized under the laws of Germany, located at D-65929 Frankfurt am Main, Germany,

the entire right, title and interest in and to my/our application for Letters Patent of the United States , executed concurrently herewith

Ser.-No.: 10/858,658

June 2, 2004

entitled: Polyamide nucleic acid derivatives, and agents and processes for preparing them

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):	111.
1ª. / Magen	/them
977	1

Date: 07-11-2004

Date:

3 rd :		_ Date:
-------------------	--	---------

DEAV 2000/A023 US NP1

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

l/we

- 1) Dr. Eugen Uhlmann, Zum Talblick 31, 61479 Glashütten, Germany
- 2) Dr. Gerhard Breipohl, Richrather Straße 246, 40723 Hilden, Germany
- 3) Dr. David William Will, Kirchstrasse 21, 65830 Kriftel, Germany

The inventors are citizens of: 1); 2) Germany 3) Great Britain

hereby sell, assign, and transfer unto Aventis Pharma Deutschland GmbH , a corporation organized under the laws of Germany, located at D-65929 Frankfurt am Main, Germany,

the entire right, title and interest in and to my/our application for Letters Patent of the United States , executed concurrently herewith

- Ser.-No. 10/858,658
- filed: June 2, 2004
- entitled: Polyamide nucleic acid derivatives, and agents and processes for preparing them

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st :		Date:
2 nd .	Jel Bregel	Date: X08/07/2004
3 rd :		Date:

PATENT REEL: 023264 FRAME: 0708

DEAV 2000/A023 US NP1

<u>ASSIGNMENT</u>

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

l/we

- 1) Dr. Eugen Uhlmann, Zum Talblick 31, 61479 Glashütten, Germany
- 2) Dr. Gerhard Breipohl, Richrather Straße 246, 40723 Hilden, Germany
- 3) Dr. David William Will, Kirchstrasse 21, 65830 Kriftel, Germany

The inventors are citizens of: 1); 2) Germany 3) Great Britain

hereby sell, assign, and transfer unto Aventis Pharma Deutschland GmbH, a corporation organized under the laws of Germany, located at D-65929 Frankfurt am Main, Germany,

the entire right, title and interest in and to my/our application for Letters Patent of the United States , executed concurrently herewith

Ser.-No. 10/858,658

filed: June 2, 2004

entitled: Polyamide nucleic acid derivatives, and agents and processes for preparing them

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st :		Date:
2 nd :		Date:
3 rd .	David W. Will.	Date: 19.07.2004

RECORDED: 09/22/2009